---
title: "biote shareholders elect directors and ratify Deloitte appointment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286825538.md"
description: "Biote Corp. held its 2026 annual meeting, where shareholders elected Andrew R. Heyer and Dana Jacoby as Class I directors until 2029. They also ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2026. The latest analyst rating for BTMD stock is a Buy with a $3.00 price target, though it faces financial risks due to negative equity and debt."
datetime: "2026-05-18T22:29:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286825538.md)
  - [en](https://longbridge.com/en/news/286825538.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286825538.md)
---

# biote shareholders elect directors and ratify Deloitte appointment

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from biote ( (BTMD) ).

On May 12, 2026, biote Corp. held its 2026 annual meeting of stockholders, where shareholders elected Andrew R. Heyer and Dana Jacoby as Class I directors to serve until the 2029 annual meeting. The voting results showed both candidates received strong support, indicating shareholder confidence in the company’s current leadership and strategic direction.

At the same meeting, stockholders ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This ratification reinforces continuity in biote’s audit oversight, supporting financial reporting stability and maintaining investor trust in the company’s governance practices.

The most recent analyst rating on (BTMD) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on biote stock, see the BTMD Stock Forecast page.

**Spark’s Take on BTMD Stock**

According to Spark, TipRanks’ AI Analyst, BTMD is a Neutral.

BTMD scores as moderately attractive: the biggest offsetting forces are elevated financial risk from negative equity and meaningful debt versus solid recent cash generation and a low P/E. Technically, shares show improving near-term momentum but remain below the 200-day average. The latest earnings call was mixed—full-year guidance was maintained, but recall- and supply-related pressures weighed on Q1 performance and are expected to impact Q2.

To see Spark’s full report on BTMD stock, click here.

**More about biote**

Biote Corp. is a Delaware-based company operating in the healthcare sector, with a focus on providing medical services and related solutions to patients and clinicians. The company’s governance structure includes a classified board, and its annual stockholder meetings serve as key forums for electing directors and confirming key corporate appointments.

**Average Trading Volume:** 256,374

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $74.04M

See more insights into BTMD stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [BTMD.US](https://longbridge.com/en/quote/BTMD.US.md)

## Related News & Research

- [17:54 ETJoint Statement Regarding Conclusion of Delaware Litigation](https://longbridge.com/en/news/286970935.md)
- [Fujimori and Sanchez advance to Peru runoff: official results](https://longbridge.com/en/news/286678277.md)
- [Colombia's ELN rebels call three-day ceasefire for presidential election](https://longbridge.com/en/news/287072814.md)
- [FACTBOX-Here are the Democrats taking early steps in potential 2028 White House bids](https://longbridge.com/en/news/286890348.md)
- [Tuberville casts doubt on Alabama redistricting: ‘I’m not so sure it’s going to go through’](https://longbridge.com/en/news/286973744.md)